Our results are the first to prove that CLI-095 treatment can significantly inhibit TLR4 downstream signaling; additionally, our results showed that treatment with CLI-095 suppressed the enhancement of aggressiveness in NSCLC cells induced by estrogen and enhanced the antitumor effect of fulvestrant. This evidence concerns the gene TLR4 and non-small cell lung carcinoma.